The deck said “strategic fit.” The IC approved. The press release landed. Twelve months later, the asset is quietly deprioritized, milestones slip, and portfolio reviews start using softer language like “optional,” “non-core,” or “revisit later.” What looked aligned at signing unravels not because the science failed, but because the fit was narrative-led rather than execution-tested. This failure mode shows up repeatedly in Pharma BD & Licensing. Teams convince themselves the deal fits the portfolio story, but the post-close operating reality tells a different story. By the time that gap is visible, value erosion is already locked in. Strategic fit is…
Browsing: Top News
ACIP vaccine schedule is under review by a panel, following changes to the hepatitis B vaccine endorsement.
FDA voucher program raises ethical concerns as experts warn of procedural risks and market impacts.
Pfizer mRNA flu shot demonstrated better protection than standard vaccines, impacting millions.
RFK Jr. profile reveals insights into his health policy stance, impacting millions of Americans.
Vaccine reformulation proposals could significantly impact manufacturers and access in over 50 countries.
Vaccine Ingredient Ban could impact U.S. childhood vaccine schedule and require costly reformulations.
Trump Kennedy vaccine policy changes could alter the U.S. childhood vaccine schedule, impacting development costs and availability.
US CDC overdose warning highlights the risk of counterfeit medicines online, with fentanyl causing over 100,000 drug overdoses annually.
EU pharmaceutical policy overhaul aims to improve access to medicines, impacting millions across Europe.